Soragni:Lab

Lawmakers to NIH: Use it or lose it.
14 Republican Senators—including key appropriators—are urging the White House to release NIH FY25 funds without delay, warning that stalled spending could harm future research budgets.
Read more: www.ascb.org/science-poli...

Yet another stop to awarding research grants. This is disastrous folks

Odds of winning NIH grants plummet as new funding policy and spending delays bite Funding multiyear grants up front will sharply cut number of investigators receiving awards

New Science story about multi-year funding and it potential catastrophic consequences

www.science.org/content/arti...

1/n

historical

This 4th percentile funding cutoff for the NCI is so very catastrophic. Assuming a 4th percentile payline corresponds to a ~5% success rate, it would take 27 grant submissions to have an 80% chance of getting just one funded. At the current submission cap of 6 apps as PI/year that means 4.5 years

NCI funding, possibly, up to 4%. Gutting cancer research because, you know, cancer is not a big health issue. Quite speechless

www.cancer.gov/grants-train...

you have a strong food-oriented branding, I think its feasible Mike.. sadly seems more reachable than funding labs at 4% 😭

tiktok

Witnessing the death of federally funded research in the US in real time is just as horrendous and shocking as you thought it may be. Will impact the country and the health of its citizens for years to come.

Hugs to you all Benoit

We are going to hear a lot in the near future about how University brass “has to make hard decisions”. Twill be interesting to see who those hard decisions land upon.

Very proud to support collaborative initiatives like this one that aim to bring biology-driven treatments to children and young adults facing rare sarcomas.

The landscape of drug sensitivity and resistance in sarcoma Al Shihabi et al. employ patient-derived tumor organoids from >110 specimens to study drug sensitivity and resistance across 21 sarcoma types. They find patient- and subtype-specific responses, correl...

Organoid platforms can provide rapid, scalable, and subtype-specific insights, with applications to drug discovery, biomarker development, and precision medicine. Access our sarcoma organoid paper here: www.cell.com/cell-stem-ce...

Our recent Cell Stem Cell work on sarcoma organoids precisely underscores the importance of developing patient-derived, human-only models to address these gaps - especially for rare sarcoma subtypes where existing tools are non-existent

This article presents a critical roadmap to guide future COG clinical trials for pediatric NRSTS, prioritizing immune checkpoint and select tyrosine kinase inhibitors, and outlining key gaps in preclinical models and data.

Happy to share a new publication from the Children’s Oncology Group, in which I had the pleasure of contributing alongside an incredible multidisciplinary team /🧵
authors.elsevier.com/a/1lPta_Lqip...

Summary Table of the massive defunding of biomedical research in the United States
www.nytimes.com/interactive/...

New strategies using AI, high-throughput platforms & predictive modeling aim to prevent acquired therapeutic resistance.

Reference
www.nature.com/articles/s41...

Acquired resistance in cancer: towards targeted therapeutic strategies - Nature Reviews Cancer Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss t...

🚨 New Article Alert! Dive into a fantastic review by several @thesfpm.bsky.social members on how new technologies and functional approaches are revolutionizing personalized cancer treatment. Don't miss out on this game-changing insight!

www.nature.com/articles/s41...

wait til they outlaw leprechauns

absolutely worth celebrating, cheers!

a man is doing push ups in a boxing ring with the words im ready behind him ALT: a man is doing push ups in a boxing ring with the words im ready behind him

POV: all is on fire but a bunch of grant deadlines are creeping in

If you weren't angry enough already, here are the rates of non-competitive renewals through May.

4008 Non-competitive renewals were due to be funded in May.

The total funded was 99!

Some is due to terminations, but most is due to slow grant making due to DOGE review and other impediments.

1/2

Wiping out hope, and progress, and generations of researchers

Sad to miss it, have fun!!

Join us this Wednesday 06/11 @ 12:00 PM EST for our monthly SFPM seminar! Dr. Chris Steffi from CompagOs will discuss: "Pioneering Solutions to Understand, Diagnose and Treat Bone Conditions"

More info & link to join: www.sfpm.io/seminars

Acquired resistance in cancer: towards targeted therapeutic strategies - Nature Reviews Cancer Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss the mechanisms of acquired resistance and the models to better study it. Finally, they promote integration of biomarker-driven strategies and cutting-edge technologies to advance predictive and proactive prevention in cancer therapy.

🚨Roadmap 🚨
Alice Soragni @alice.soragnilab.com‬, Erik S. Knudsen ‪@roswellpark.bsky.social‬ ‪ & Co discuss the mechanisms of acquired resistance and the models to better study it to advance predictive and proactive prevention in cancer therapy.
📖 ⬇️

The State of Science: Moving Beyond ‘Good Faith’ Negotiations Challenging an implicit assumption in ongoing dialogues on the future of American science: do we really want the same thing?

"If leadership in major science organizations continue to hew closely to administration talking points as a means to steer policy decisions, the public may perceive that bad-faith arguments of the White House have broader legitimacy amongst scientists." 🧪

open.substack.com/pub/joshuasw...

Acquired resistance in cancer: towards targeted therapeutic strategies - Nature Reviews Cancer Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss t...

Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Acquired Resistance in Cancer: Towards Targeted Therapeutic Strategies
doi.org/10.1038/s415...

Acquired resistance in cancer: towards targeted therapeutic strategies - Nature Reviews Cancer Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss t...

Acquired resistance limits the efficacy of cancer treatments & accounts for therapy failure in most patients. Our Roadmap explores how innovative technologies bridge the gap between fundamental research on resistance and clinical translation into actionable strategies
www.nature.com/articles/s41...